Claudio Ronco1, Luca Di Lullo2. 1. International Renal Research Institute (IRRIV), S. Bortolo Hospital, Vicenza, Italy. 2. Department of Nephrology and Dialysis, L. Parodi-Delfino Hospital, Colleferro, Italy.
Abstract
BACKGROUND: It is well established that a large number of hospitalized patients present various degrees of heart and kidney dysfunction; primary disease of the heart or kidney often involves dysfunction or injury to the other. SUMMARY: Based on above-cited organ cross-talk, the term cardiorenal syndrome (CRS) was proposed. Although CRS was usually referred to as abruption of kidney function following heart injury, it is now clearly established that it can describe negative effects of an impaired renal function on the heart and circulation. The historical lack of clear syndrome definition and complexity of diseases contributed to a waste of precious time especially concerning diagnosis and therapeutic strategies. The effective classification of CRS proposed in a Consensus Conference by the Acute Dialysis Quality Group essentially divides CRS into two main groups, cardiorenal and renocardiac CRS, on the basis of primum movens of disease (cardiac or renal); both cardiorenal and renocardiac CRS are then divided into acute and chronic according to disease onset. Type 5 CRS integrates all cardiorenal involvement induced by systemic disease. KEY MESSAGES: Prevalence and incidence data show a widespread increase of CRS also due to an increasing incidence of acute and chronic cardiovascular disease, such as acute decompensated heart failure, arterial hypertension and valvular heart disease. Patients with chronic kidney disease present various degrees of cardiovascular involvement especially due to chronic inflammatory status, volume and pressure overload and secondary hyperparathyroidism leading to a higher incidence of calcific heart disease. The following review will focus on the main aspects (epidemiology, risk factors, diagnostic tools and protocols, therapeutic approaches) of CRS in Western countries (Europe and United States).
BACKGROUND: It is well established that a large number of hospitalized patients present various degrees of heart and kidney dysfunction; primary disease of the heart or kidney often involves dysfunction or injury to the other. SUMMARY: Based on above-cited organ cross-talk, the term cardiorenal syndrome (CRS) was proposed. Although CRS was usually referred to as abruption of kidney function following heart injury, it is now clearly established that it can describe negative effects of an impaired renal function on the heart and circulation. The historical lack of clear syndrome definition and complexity of diseases contributed to a waste of precious time especially concerning diagnosis and therapeutic strategies. The effective classification of CRS proposed in a Consensus Conference by the Acute Dialysis Quality Group essentially divides CRS into two main groups, cardiorenal and renocardiac CRS, on the basis of primum movens of disease (cardiac or renal); both cardiorenal and renocardiac CRS are then divided into acute and chronic according to disease onset. Type 5 CRS integrates all cardiorenal involvement induced by systemic disease. KEY MESSAGES: Prevalence and incidence data show a widespread increase of CRS also due to an increasing incidence of acute and chronic cardiovascular disease, such as acute decompensated heart failure, arterial hypertension and valvular heart disease. Patients with chronic kidney disease present various degrees of cardiovascular involvement especially due to chronic inflammatory status, volume and pressure overload and secondary hyperparathyroidism leading to a higher incidence of calcific heart disease. The following review will focus on the main aspects (epidemiology, risk factors, diagnostic tools and protocols, therapeutic approaches) of CRS in Western countries (Europe and United States).
Entities:
Keywords:
Cardiorenal syndrome; Diagnosis; Outcomes; Risk factors; Treatment; Western countries
Authors: Luca Di Lullo; Vincenzo Barbera; Alberto Santoboni; Antonio Bellasi; Mario Cozzolino; Antonio De Pascalis; Rodolfo Rivera; Alessandro Balducci; Domenico Russo; Claudio Ronco Journal: G Ital Nefrol Date: 2015 Jul-Aug
Authors: Antoine G Schneider; Rinaldo Bellomo; Sean M Bagshaw; Neil J Glassford; Serigne Lo; Min Jun; Alan Cass; Martin Gallagher Journal: Intensive Care Med Date: 2013-02-27 Impact factor: 17.440
Authors: Milan Stengl; Frantisek Bartak; Roman Sykora; Jiri Chvojka; Jan Benes; Ales Krouzecky; Ivan Novak; Jitka Sviglerova; Jitka Kuncova; Martin Matejovic Journal: Crit Care Med Date: 2010-02 Impact factor: 7.598
Authors: L Di Lullo; F Floccari; R Rivera; V Barbera; A Granata; G Otranto; A Mudoni; M Malaguti; A Santoboni; C Ronco Journal: Cardiorenal Med Date: 2013-07 Impact factor: 2.041
Authors: Hans L Hillege; Dorothea Nitsch; Marc A Pfeffer; Karl Swedberg; John J V McMurray; Salim Yusuf; Christopher B Granger; Eric L Michelson; Jan Ostergren; Jan Hein Cornel; Dick de Zeeuw; Stuart Pocock; Dirk J van Veldhuisen Journal: Circulation Date: 2006-02-07 Impact factor: 29.690
Authors: Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin Journal: Crit Care Date: 2007 Impact factor: 9.097
Authors: Lei Zhang; Xiang-Yang Zhu; Yu Zhao; Alfonso Eirin; Lei Liu; Christopher M Ferguson; Hui Tang; Amir Lerman; Lilach O Lerman Journal: Basic Res Cardiol Date: 2020-01-14 Impact factor: 17.165
Authors: Agata Bielecka-Dabrowa; Breno Godoy; Joerg C Schefold; Michael Koziolek; Maciej Banach; Stephan von Haehling Journal: Curr Heart Fail Rep Date: 2018-08
Authors: Rumie Wakasaki; Katsuyuki Matsushita; Kirsti Golgotiu; Sharon Anderson; Mahaba B Eiwaz; Daniel J Orton; Sang Jun Han; H Thomas Lee; Richard D Smith; Karin D Rodland; Paul D Piehowski; Michael P Hutchens Journal: JCI Insight Date: 2019-02-21
Authors: Maria Prothasis; Anuj Varma; Shilpa Gaidhane; Sunil Kumar; Nazli Khatib; Quazi S Zahiruddin; Abhay Gaidhane Journal: J Family Med Prim Care Date: 2020-08-25
Authors: Bruce A Molitoris; Anthony G George; Patrick T Murray; Daniel Meier; Erinn S Reilly; Erin Barreto; Ruben M Sandoval; Dana V Rizk; Andrew D Shaw; W Frank Peacock Journal: Cardiorenal Med Date: 2019-03-07 Impact factor: 2.041
Authors: Linsey J F Peters; Jürgen Floege; Erik A L Biessen; Joachim Jankowski; Emiel P C van der Vorst Journal: Int J Mol Sci Date: 2020-09-07 Impact factor: 5.923